Last updated: February 26, 2026
What is the Drug NDC 43598-0941?
The National Drug Code (NDC) 43598-0941 identifies a specific biologic product marketed by a pharmaceutical company. Based on publicly available databases, the NDC corresponds to Herceptin (trastuzumab), a monoclonal antibody used primarily for HER2-positive breast and gastric cancers.
Market Size and Growth Potential
Current Market Landscape
| Data Point |
Details |
| Therapeutic Area |
Oncology (HER2-positive breast/gastric cancer) |
| Estimated Global Market Size (2022) |
$8.5 billion |
| US Market Share (2022) |
$3.1 billion |
| Growth Rate (CAGR 2023-2028) |
7% annually |
| Major Competitors |
Perjeta (pertuzumab), Kadcyla (ado-trastuzumab emtansine), Tykerb (lapatinib) |
Market Drivers
- Increased diagnosis rates of HER2-positive cancers.
- Expansion into adjuvant and neoadjuvant settings.
- Introduction of biosimilars lowering prices and expanding access.
- FDA approvals for new indications.
Market Constraints
- High treatment costs.
- Patent expirations and biosimilar competition reducing pricing power.
- Price sensitivity in emerging markets.
Price Trends and Projections
Current Pricing Environment
- Brand-Name Herceptin (US, 2023):
- Vial Price: Approximately $1,850 per 600 mg dose.
- Cost per treatment course (e.g., 6 cycles): ~$11,100.
- Biosimilars (Approved in US 2019):
- Average Price: 20-30% lower than originator, around $1,300-$1,500 per vial.
- Impact: Reduced manufacturer revenue, increased access.
Historical Price Changes
| Year |
Average Vial Price (USD) |
Notes |
| 2015 |
$2,100 |
Initial pricing dominance |
| 2018 |
$1,950 |
Steady decline due to biosimilar entry preparations |
| 2020 |
$1,850 |
Price stabilization, biosimilar proliferation |
| 2023 |
$1,850 |
Pricing stabilized with biosimilar competition |
Price Projections (2024-2028)
| Year |
Estimated Vial Price (USD) |
Drivers |
| 2024 |
$1,780 |
Biosimilar competition pressures |
| 2025 |
$1,700 |
Market saturation, cost containment efforts |
| 2026 |
$1,620 |
Increased biosimilar penetration |
| 2027 |
$1,530 |
Price stabilization with new biosimilar entrants |
| 2028 |
$1,450 |
Likely plateauing as market matures |
Revenue Implication Estimation
Assuming an average patient receives 6 cycles of treatment:
| Year |
Estimated Revenue per Patient (USD) |
Comments |
| 2024 |
$10,680 |
Price decrease impacts revenue |
| 2025 |
$10,200 |
Steady decline continues |
| 2026 |
$9,720 |
Continued biosimilar effect |
| 2027 |
$9,180 |
Price stabilization slows revenue drop |
| 2028 |
$8,700 |
Revenue stabilizes, demand driven by new indications |
Regulatory and Policy Environment
- FDA approved multiple biosimilars since 2019, contributing to market competition.
- Harmonization of biosimilar approval pathways globally affects pricing strategies.
- Price control policies in countries like the UK, Canada, and some EU nations exert downward pressure.
Strategic Considerations
- Biosimilar adoption influences future pricing and market share.
- Expansion into new indications might sustain higher pricing temporarily.
- Mergers and partnerships may affect market dynamics and pricing strategies.
Key Takeaways
- NDC 43598-0941 corresponds to Herceptin, a dominant product in HER2-positive cancer therapy.
- Market size exceeds $8 billion globally with a CAGR of 7%, stabilizing with biosimilar entries.
- Current US vial prices average $1,850, with projections indicating a decline to around $1,450 by 2028.
- Biosimilar competition and regulatory policies are the primary drivers influencing future pricing.
- Revenue impact aligns with price trends; demand remains stable due to broad therapeutic adoption.
FAQs
What factors primarily influence the price of Herceptin (NDC 43598-0941)?
Market competition from biosimilars, regulatory policies, patent expirations, and manufacturing costs influence pricing.
How will biosimilars impact future pricing?
Biosimilars are expected to reduce drug prices by 20-30%, creating downward pressure on the originator's pricing and revenues.
What is the expected growth for the HER2-positive cancer market?
The market is projected to grow at a CAGR of 7% between 2023 and 2028 due to rising diagnosis rates and new indication approvals.
How does the regulatory environment affect price projections?
Regulatory approvals of biosimilars and policies on drug pricing directly impact market competition and pricing strategies.
Are there geographic differences in pricing trends?
Yes. US market prices are higher than in Europe or emerging markets, where price controls and healthcare policies influence costs.
References
[1] IQVIA Institute. (2022). The Global Use of Medicines in 2022. IQVIA.
[2] FDA. (2022). Approval of biosimilars for trastuzumab. U.S. Food and Drug Administration.
[3] Fierce Pharma. (2023). Herceptin biosimilars: Pricing and market trends. FiercePharma.com.
[4] Statista. (2023). Oncology drug market size and projections. Statista.
[5] European Medicines Agency. (2022). Biosimilar medicines overview. EMA.
